Succeed in Managing Cardiovascular Risk in Diabetes (SIM-CVRiD) is a multi-stakeholder, multi-sponsor effort to explore cardiovascular risk management in patients with Type 2 diabetes who have established cardiovascular disease or who are at high risk. Recognizing that the emergence of recent trial data demonstrating cardio-protective benefits in novel antidiabetic therapies has generated increased interest and new questions among the cardiovascular team, the ACC is dedicated to facilitating a greater understanding of real-life challenges faced by patients, caregivers, clinicians, payers and health systems in incorporating this exciting new evidence into practice.

SIM-CVRiD represents the next frontier, building off the conclusions from ACC's recent multidisciplinary stakeholder roundtables and transforming those insights into tools and resources for clinicians and their patients to use at the point of care.

Components of SIM-CVRiD include:

• Managing CV Disease Risk in Diabetes Roundtables: These roundtables are designed to address recent trial evidence for new antidiabetic drugs, their demonstrated improved cardiovascular outcomes and what that means for the cardiology community. The roundtables also serve as forums for clinical experts and other representatives to engage in deeper discussions around pressing clinical issues and other questions that have emerged alongside new clinical trial data. Participants address key questions facing clinicians and work towards identifying solutions to overcoming the gaps in knowledge and barriers to care.
• Diabetes and Cardiometabolic Disease Topic Collection: A page dedicated to diabetes and cardiometabolic disease that features relevant news articles, case challenges, and relevant resources. The objective of this page is to provide a centralized location for new scientific information on managing cardiovascular disease risk in diabetic patients.
• Clinician Tools:
  • Handbook on ASCVD and Type 2 Diabetes: This booklet is intended to provide guidance for cardiovascular clinicians who are managing patients with type 2 diabetes with established ASCVD or at high risk for ASCVD.
    Also available in Portuguese and Arabic.
  • Guidance For Initiating and Monitoring SGLT2 Inhibitors and GLP-1RAs: This tool includes key considerations clinicians should make concerning the use of a GLP-1RA or SGLT2i for CV risk reductions in patients with T2D.
  • Meeting in a Box: This tool contains all the resources you need to successfully host your own educational activity to share the latest research and practice tools regarding cardiovascular risk in diabetes.
  • Type 2 Diabetes Cardiovascular Risk Discussion Guide: This tool offers clinicians tips for talking with patients about diabetes and cardiovascular risk, as well as the heart-related benefits of two classes of antiglycemic medications. It provides a roadmap to help improve CV risk management in people with diabetes, as well as tools to facilitate conversations with patients at the point of care.
    • For a quick summary of important points, read 6 steps for Optimizing Cardiovascular Risk Reduction Among Patients With Diabetes.
• Patient Resources: Educational materials and tools developed to increase patient engagement and improve the patient-clinician dialogue are available in the CardioSmart Diabetes and Heart Disease resource center.
  • Your Action Plan for Managing Diabetes and Protecting Your Heart: Patients use this workbook to write down their goals and map out a plan to lower their risk of diabetes-related heart problems.
  • 10 Steps to Lower Your Chance of Diabetes-Related Heart Problems: Checklist helps patients manage diabetes to lower the chance of related heart problems.
  • My Medication List: Worksheet helps patients track their medications and questions to talk about with their care teams.
  • What You Need to Know: Diabetes & Heart Disease Patient Tool: This tool shows patients how having type 2 diabetes puts them at greater risk of heart disease.

SIM-CVRiD is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company. The 2017 and 2018 Managing CV Disease Risk in Diabetes Roundtables were supported by AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Novo Nordisk Inc.